Government ❯ Federal Agencies

FDA

Drug Regulation Drug Approval Process Regulatory Actions Health and Human Services Drug Approval Medication Abortion Regulatory Authority Biologics Evaluation Regulatory Oversight Electronic Cigarettes DOJ Task Forces Drug Approvals Vaccine Regulation Food and Drug Administration FTC Tobacco Products Health Regulations EPA Food Safety Public Health Leadership Chief Counsel Covid vaccine approval Approval Process Drug Enforcement Drug Oversight Drug Regulations CDC Public Health Policy HHS Leadership Policy Review Public Health Oversight Leadership Changes Drug Advertising Crackdown Health Policies Policy Decisions Commissioners Health Policy Health Administration Food Safety Oversight Food Traceability Public Health

Overton Dodges Key Science Questions at Senate FDA Hearing

Her pledge to make the FDA’s mifepristone safety review an immediate priority comes as the agency must report to a court on Oct. 7.

White House Restarts Pandemic Office With Two Officials but Little Staff

Virginia Judge Orders FDA to Reconsider 2023 Abortion‑Pill Restrictions

FDA Launches Retrospective Safety Study of Mifepristone

Jury Convicts California Lab Owner in Scheme to Sell Over 1 Million Bogus COVID Tests

Judge Pauses Louisiana Abortion-Pill Case and Orders FDA Review Update in Six Months

Watchdog Says Minors Can Buy Cross-Sex Hormones Online With 'Alarming Ease'

FDA Biologics Chief Vinay Prasad to Step Down at End of April

FDA Warns 30 Telehealth Firms Over Misleading Ads for Compounded GLP-1 Drugs

Savannah Bee Recalls Honey BBQ Sauce-Mustard Nationwide Over Allergen Mislabeling

Louisiana’s Challenge to FDA’s Mifepristone Mail-Order Rule Heard in Federal Court

Texas and Florida Sue FDA to Overturn Mifepristone Approvals and Mail-Order Access

DOJ Seizes 73,000 Suspected 7‑OH Products From Kansas City Warehouses

FDA Confirms Safety Review of Mifepristone With No Regulatory Changes Yet

Democratic-Led States Petition FDA to Remove Mifepristone Restrictions